Skip to content

Home page linkHelp page linkFamily support page linkPrescribe page linkData page linkMaterials page link 

The Surgeon General's call to end the opioid crisis starts with you.

Think about preventing addiction before you prescribe

Use the PDMP

    Want to help address the opioid misuse epidemic in Alaska? Please register for Alaska’s Prescription Drug Monitoring Program if you haven’t already, and use it regularly. This patient safety tool can help you detect whether your patients are getting multiple prescriptions and are at risk of misusing or abusing opioids. For more information, visit

Continuing education on opioids, pain management and addiction

    New Alaska legislation requires a minimum of two hours of continuing education in pain management, opioid use and addiction (unless you
    do not hold a valid DEA registration). We’ve curated list of several accredited online courses​ that can be used to fulfill the new CME/CNE requirement.

Knowing the risk factors

    People of every age, gender and social status have become addicted to opioids. It’s important to talk about the risk factors with everyone.

    When making the decision to prescribe opioids rather than using other therapy for pain, ask about previous drug use, history of substance abuse disorder or overdose, benzodiazepine use, sleep-disordered breathing, and other co-existing mental health conditions such as depression, anxiety and PTSI.

    Always focus on functional goals and improvement, and set the criteria for stopping or continuing use. Talk to patients about how opioid therapy will be discontinued if its benefits do not outweigh the risks.

    Go low dose by using the lowest dosage on the product’s labeling. Match the duration of use with the next scheduled reassessment.

Monitor and reassess

PCSS MAT training

MATx mobile app supports medication-assisted treatment

This free app 1) helps providers learn how to get certified to prescribe buprenorphine for opioid-addiction, 2) has a treatment locator for people looking for treatment, and 3) lets pharmacists verify that prescribers are certified.

    It supports practitioners who currently provide medication-assisted treatment (MAT), as well as those who plan to do so in the future, empowering them to provide effective, evidence-based care for opioid use disorders.

    MATx features for practitioners and patients include:
      • Information on treatment approaches and medications approved by the U.S. Food and Drug Administration for use in the treatment of opioid use disorders
      • A buprenorphine prescribing guide, which includes information on the Drug Addiction Treatment Act of 2000 waiver process and patient limits
      • Clinical support tools, such as treatment guidelines, ICD-10 coding, and recommendations for working with special populations
      • Access to critical helplines and SAMHSA’s treatment locators.